Larkin Community Hospital Neurology

Residency · South Miami, FL

Sponsored by Larkin Community Hospital · Director Wilson Cueva

Works by its people: 449
Authors: 40
First-author works: 89
Citations: 11,868

20112026

Topics

Parkinson's Disease Mechanisms and Treatments 76
Neurological disorders and treatments 20
Genetic Neurodegenerative Diseases 13
Epilepsy research and treatment 12
Multiple Sclerosis Research Studies 11
Cardiovascular Syncope and Autonomic Disorders 10
Botulinum Toxin and Related Neurological Disorders 9
CNS Lymphoma Diagnosis and Treatment 8
Traumatic Brain Injury and Neurovascular Disturbances 7
Autoimmune Neurological Disorders and Treatments 6
Cerebral Venous Sinus Thrombosis 6
COVID-19 Clinical Research Studies 5

Most cited

Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies.
JAMA · 2024 · 170 citations · Stuart Isaacson
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Brain : a journal of neurology · 2024 · 89 citations · Stuart Isaacson
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
The Lancet. Neurology · 2024 · 72 citations · Stuart Isaacson
Medical Cannabis for Chronic Nonmalignant Pain Management.
Current pain and headache reports · 2023 · 40 citations · Samir Ruxmohan
Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.
JAMA neurology · 2026 · 9 citations · Stuart Isaacson
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.
Movement disorders clinical practice · 2026 · 8 citations · Stuart Isaacson
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial.
JAMA neurology · 2023 · 38 citations · Stuart Isaacson
Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.
Clinical parkinsonism & related disorders · 2023 · 37 citations · Stuart Isaacson

Topics

Parkinson's Disease Mechanisms and Treatments 76

Neurological disorders and treatments 20

Genetic Neurodegenerative Diseases 13

Epilepsy research and treatment 12

Multiple Sclerosis Research Studies 11

Cardiovascular Syncope and Autonomic Disorders 10

Botulinum Toxin and Related Neurological Disorders 9

CNS Lymphoma Diagnosis and Treatment 8

Traumatic Brain Injury and Neurovascular Disturbances 7

Autoimmune Neurological Disorders and Treatments 6

Cerebral Venous Sinus Thrombosis 6

COVID-19 Clinical Research Studies 5

Most cited

Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies.

JAMA · 2024 · 170 citations · Stuart Isaacson

Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.

Brain : a journal of neurology · 2024 · 89 citations · Stuart Isaacson

Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.

The Lancet. Neurology · 2024 · 72 citations · Stuart Isaacson

Medical Cannabis for Chronic Nonmalignant Pain Management.

Current pain and headache reports · 2023 · 40 citations · Samir Ruxmohan

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.

JAMA neurology · 2026 · 9 citations · Stuart Isaacson

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.

Movement disorders clinical practice · 2026 · 8 citations · Stuart Isaacson

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial.

JAMA neurology · 2023 · 38 citations · Stuart Isaacson

Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.

Clinical parkinsonism & related disorders · 2023 · 37 citations · Stuart Isaacson